Breaking: Pfizer (NYSE:PFE) “Buy” Rating Reaffirmed by Analysts at Piper Jaffray Today; The Price Target is $54.0

January 22, 2018 - By Hazel Jackson

 Breaking: Pfizer (NYSE:PFE)

Investors sentiment increased to 0.96 in Q3 2017. Its up 0.02, from 0.94 in 2017Q2. It is positive, as 53 investors sold Pfizer Inc. shares while 700 reduced holdings. 106 funds opened positions while 620 raised stakes. 4.06 billion shares or 0.86% more from 4.02 billion shares in 2017Q2 were reported.

Vigilant Capital Mgmt Limited has 0.21% invested in Pfizer Inc. (NYSE:PFE) for 39,042 shares. Geode Llc stated it has 61.24M shares or 0.81% of all its holdings. Wedgewood Invsts Pa reported 14,774 shares. Ftb Advisors has invested 0.61% of its portfolio in Pfizer Inc. (NYSE:PFE). Nbt Bankshares N A stated it has 216,485 shares or 1.24% of all its holdings. Gemmer Asset Ltd Liability holds 33,825 shares or 0.46% of its portfolio. 7,644 are held by Ronna Sue Cohen. Whittier Of Nevada stated it has 0.99% in Pfizer Inc. (NYSE:PFE). Hodges Cap Mngmt holds 0.01% or 5,649 shares in its portfolio. 261,375 were reported by Lvm Capital Mngmt Limited Mi. Wendell David Associates holds 0.37% of its portfolio in Pfizer Inc. (NYSE:PFE) for 59,013 shares. Smead accumulated 1.91M shares. Partner Fund Mgmt L P stated it has 1.07% in Pfizer Inc. (NYSE:PFE). The New York-based Sandler Capital Mngmt has invested 0.14% in Pfizer Inc. (NYSE:PFE). Redmond Asset Mngmt Limited Liability Company reported 0.19% in Pfizer Inc. (NYSE:PFE).

Since August 4, 2017, it had 0 insider buys, and 10 sales for $16.36 million activity. $3.21M worth of Pfizer Inc. (NYSE:PFE) shares were sold by DAMELIO FRANK A. $296,560 worth of stock was sold by JOHNSON RADY A on Friday, December 15. READ IAN C had sold 197,168 shares worth $6.70M. $1.34M worth of stock was sold by SUSMAN SALLY on Tuesday, September 12. 8,064 shares valued at $263,693 were sold by OLSON LAURIE J on Monday, August 21.

Pfizer (NYSE:PFE) Rating Reaffirmed

The company has just set a price target of $54.0 on Pfizer (NYSE:PFE) shares. This is 46.14 % from the last stock price. In an analyst report revealed to investors and clients on Tuesday, 31 October, Piper Jaffray maintained their “Buy” rating on shares of PFE.

Investors sentiment increased to 0.96 in Q3 2017. Its up 0.02, from 0.94 in 2017Q2. It is positive, as 53 investors sold Pfizer Inc. shares while 700 reduced holdings. 106 funds opened positions while 620 raised stakes. 4.06 billion shares or 0.86% more from 4.02 billion shares in 2017Q2 were reported.

Vigilant Capital Mgmt Limited has 0.21% invested in Pfizer Inc. (NYSE:PFE) for 39,042 shares. Geode Llc stated it has 61.24M shares or 0.81% of all its holdings. Wedgewood Invsts Pa reported 14,774 shares. Ftb Advisors has invested 0.61% of its portfolio in Pfizer Inc. (NYSE:PFE). Nbt Bankshares N A stated it has 216,485 shares or 1.24% of all its holdings. Gemmer Asset Ltd Liability holds 33,825 shares or 0.46% of its portfolio. 7,644 are held by Ronna Sue Cohen. Whittier Of Nevada stated it has 0.99% in Pfizer Inc. (NYSE:PFE). Hodges Cap Mngmt holds 0.01% or 5,649 shares in its portfolio. 261,375 were reported by Lvm Capital Mngmt Limited Mi. Wendell David Associates holds 0.37% of its portfolio in Pfizer Inc. (NYSE:PFE) for 59,013 shares. Smead accumulated 1.91M shares. Partner Fund Mgmt L P stated it has 1.07% in Pfizer Inc. (NYSE:PFE). The New York-based Sandler Capital Mngmt has invested 0.14% in Pfizer Inc. (NYSE:PFE). Redmond Asset Mngmt Limited Liability Company reported 0.19% in Pfizer Inc. (NYSE:PFE).

Since August 4, 2017, it had 0 insider buys, and 10 sales for $16.36 million activity. $3.21M worth of Pfizer Inc. (NYSE:PFE) shares were sold by DAMELIO FRANK A. $296,560 worth of stock was sold by JOHNSON RADY A on Friday, December 15. READ IAN C had sold 197,168 shares worth $6.70M. $1.34M worth of stock was sold by SUSMAN SALLY on Tuesday, September 12. 8,064 shares valued at $263,693 were sold by OLSON LAURIE J on Monday, August 21.

Pfizer Inc. (NYSE:PFE) Ratings Coverage

Among 21 analysts covering Pfizer (NYSE:PFE), 9 have Buy rating, 1 Sell and 11 Hold. Therefore 43% are positive. Pfizer has $54.0 highest and $33.0 lowest target. $38.67’s average target is 4.67% above currents $36.945 stock price. Pfizer had 68 analyst reports since July 29, 2015 according to SRatingsIntel. On Tuesday, June 14 the stock rating was maintained by Jefferies with “Buy”. BMO Capital Markets maintained it with “Hold” rating and $33 target in Friday, April 28 report. Suntrust Robinson upgraded the stock to “Neutral” rating in Wednesday, November 25 report. The firm earned “Outperform” rating on Monday, May 9 by Credit Suisse. The rating was maintained by Jefferies on Thursday, April 7 with “Buy”. The firm has “Neutral” rating by Credit Suisse given on Thursday, July 20. The firm earned “Hold” rating on Wednesday, April 6 by Societe Generale. On Wednesday, November 25 the stock rating was upgraded by SunTrust to “Neutral”. Cowen & Co maintained the shares of PFE in report on Monday, September 18 with “Buy” rating. On Thursday, July 13 the stock rating was maintained by Jefferies with “Hold”.

The stock increased 0.01% or $0.005 during the last trading session, reaching $36.945. About 7.54M shares traded. Pfizer Inc. (NYSE:PFE) has declined 2.76% since January 22, 2017 and is downtrending. It has underperformed by 19.46% the S&P500.

Analysts await Pfizer Inc. (NYSE:PFE) to report earnings on January, 30. They expect $0.56 earnings per share, up 19.15 % or $0.09 from last year’s $0.47 per share. PFE’s profit will be $3.34 billion for 16.49 P/E if the $0.56 EPS becomes a reality. After $0.67 actual earnings per share reported by Pfizer Inc. for the previous quarter, Wall Street now forecasts -16.42 % negative EPS growth.

Pfizer Inc. discovers, develops, manufactures, and sells healthcare products worldwide. The company has market cap of $220.22 billion. It operates through two divisions, Pfizer Innovative Health and Pfizer Essential Health (EH). It has a 22.82 P/E ratio. The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

More notable recent Pfizer Inc. (NYSE:PFE) news were published by: Fool.com which released: “The case for Gilead Sciences” on January 21, 2018, also Investorplace.com with their article: “3 Reasons Dividend-Monster Pfizer Inc. Could Explode Higher” published on January 12, 2018, Seekingalpha.com published: “Pfizer: The Best Big Pharma Dividend Stock” on January 21, 2018. More interesting news about Pfizer Inc. (NYSE:PFE) were released by: Seekingalpha.com and their article: “Hold On To Pfizer In 2018” published on December 29, 2017 as well as Investorplace.com‘s news article titled: “Why Pfizer Inc. Stock Is One of the Few Safe Drug Stocks” with publication date: December 26, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.